In the previous funding period, we have demonstrated that: 1) Vascular Endothelial Growth Factor (VEGF), a pro-angiogenic factor produced by most human solid tumors has profound effects on hematopoiesis, specifically inhibition of Dendritic Cell (DC) differentiation and diversion of progenitors to other myeloid lineages; 2) blockade of VEGF reverses this effect in both animals and humans and significantly improves the efficacy of immunotherapy in animal models; 3) T cell differentiation is inhibited as well, inducing rapid thymic involution and diversion of lymphocytes toward B-cell differentiation, also contributing to immunosuppression; 4) VEGF-induced immunosuppression associates with dramatic expansion of immunosupressive immature myeloid cells (ImCs) capable of directly inhibiting T cell responses; 5) that treatment with retinoids promotes differentiation of these ImCs; and 6) in contrast to most known VEGF responses, VEGF receptor 1 (VEGFR1) is a major mediator of VEGF effects on immune cells and indicate involvement of tyrosine kinase-independent signaling in this process. In the next funding period, we will focus on a molecular understanding of the involved receptors and signal transduction mechanisms of VEGF effects on hematopoiesis, characterizing the effects of VEGF on T-cells and ImCs, preclinical studies of retinoids for reversial of this immunosuppression, and translation of our VEGF findings into a human therapeutic clinical trial. In our animal models we will use antibodies, specific tyrosine kinase inhibitors, and transgenic mice as molecular probes to assess the roles of both VEGF receptors and their tyrosine kinases in vivo.
We aim to screen candidate retinoids in preclinical studies of treatment targeting removal of ImCs and restoring of DC function. The clinical relevance of our findings will be tested in a phase 1/11trial co-sponsored by Cell Genesys, Inc. and CTEP combining the GVAX ?vaccine with anti-VEGF antibody in advanced non-small cell lung cancer. Our studies have thus identified and characterized a novel and significant mechanism for dysregulation of hematopoiesis leading to immunosuppression in tumor bearing hosts and the proposed studies will clarify the mechanism of this effect and directly translate our findings into therapeutic hypotheses to be tested in a human clinical trial.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA076321-06A2
Application #
6731639
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Hecht, Toby T
Project Start
1997-12-15
Project End
2008-08-31
Budget Start
2003-09-30
Budget End
2004-08-31
Support Year
6
Fiscal Year
2003
Total Cost
$319,365
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Carbone, David P; Gandara, David R; Antonia, Scott J et al. (2015) Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 10:974-84
Huang, Yuhui; Lin, Luping; Shanker, Anil et al. (2011) Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res 71:6122-31
Novitskiy, Sergey V; Csiki, Ildiko; Huang, Yuhui et al. (2010) Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cells. J Thorac Oncol 5:1410-5
Novitskiy, Sergey V; Ryzhov, Sergey; Zaynagetdinov, Rinat et al. (2008) Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112:1822-31
Yang, Li; Huang, Jianhua; Ren, Xiubao et al. (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23-35
Ryzhov, Sergey; Novitskiy, Sergey V; Zaynagetdinov, Rinat et al. (2008) Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 10:987-95
Huang, Yuhui; Chen, Xiaolan; Dikov, Mikhail M et al. (2007) Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110:624-31
Csiki, Ildiko; Yanagisawa, Kiyoshi; Haruki, Nobuhiro et al. (2006) Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res 66:143-50
Dikov, Mikhail M; Ohm, Joyce E; Ray, Neelanjan et al. (2005) Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 174:215-22
Csiki, Ildiko; Morrow, Jason D; Sandler, Alan et al. (2005) Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 11:6634-40

Showing the most recent 10 out of 18 publications